Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.
Research suggests that directors know their companies better than the market. For many investors it is intuitive that following the trading patterns of directors and other company insiders can lead to successful investing. They often have detailed knowledge about their companies and generally know when the shares are incorrectly valued. However, that is not always true and with large numbers of trades reported every day on exchanges around the world, it is difficult to know which to follow.
SmartInsider provides valuable insight by supplementing and analysing reported transactions to achieve real insight with a focus on identifying the ‘Smart Insiders’ and highlighting the stand-out transactions they make. Our proven track-record and thirty year pedigree are backed by more recent statistical analysis of historical data.
Our service offers director dealing reports, company reports and monthly summaries with a fully interactive website for further research. We can also provide quant feeds and customised alerts to suit every need at the frequency preferred. SmartInsider covers all markets with a regulatory requirement to report insider activity, over 60,000 companies across 55 markets.
ZEALAND - BUY | DKK180 vs. DKK143 (+31%) The right CEO, at the right time, to convey new messages and prepare for the next phase First very positive impression from first meeting with new CEO Glepaglutide should do better than Gattex Dasiglucagon: a multi-dimensional discussion to conduct
>Q1 2019 results - Zealand Pharma yesterday afternoon reported its financial results for Q1 2019. No sales recorded over the period (after the sale of the rights for Soliqua and Lyxumia to Royalty Pharma last September), the operating loss widened to DKK 136m (vs -DKK 88m in Q1 2018) underscoring the decline in revenues and the rise in opex (R&D +36% to DKK 121m; +80% SG&A to DKK 14.5m) which reflects the progress of the development of the various molecules in its pip...
Two Directors at Summit Financial Group Inc bought/sold 8,176 shares at 25.000USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...
A director at Boule Diagnostics AB bought 3,750 shares at 53.360SEK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.